PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
David F. McDermott, MD - Making Effective Therapeutic Choices for Advanced RCC in an Evolving Treatment Landscape: Personal Insights From the Patient CaseBook
Go online to PeerView.com/FEJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts to decision-making in a complex therapeutic landscape, the expert panel explores how best to leverage the potency of newer agents across different RCC settings. Upon completion of this activity, participants should be better able to: Assess the latest evidence with and clinical implications of novel approaches, including new targeted agents, immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Apply recently validated immunotherapy and targeted therapy options effectively for patients with advanced RCC that reflect optimal patient-centric selection and sequencing through multiple lines of therapy, Employ effective strategies to prevent and/or manage treatment-related complications with multi-targeted TKIs and immune checkpoint inhibitor therapy in patients with RCC, Recommend ongoing clinical trials assessing the latest therapies and/or combination approaches for advanced RCC patients in different disease settings.